The Food and Drugs Authority (FDA) has ordered the recall of Arcan Bitters from the Ghanaian market. This action follows laboratory tests that found the alcoholic drink adulterated with Sildenafil Citrate, a prescription-only drug.
The FDA has given Unni Associates Company Limited, the manufacturer, 14 days to remove the product. The company's manufacturing facility in Parkoso, Asokore Mampong Municipality, Ashanti Region, has also been shut down. Sildenafil Citrate, a Phosphodiesterase Type 5 (PDE5) inhibitor, is not permitted in food products. Arcan Bitters was registered as an alcoholic beverage, not a drug-containing substance.
This incident underscores the FDA's ongoing efforts to safeguard public health and ensure product safety in Ghana. The Authority frequently conducts market surveillance and laboratory analyses to detect non-compliant products. Previous actions include shutting down food manufacturing facilities and warning against unauthorised chemicals in food. Such regulatory interventions are crucial for maintaining consumer trust and upholding industry standards. The FDA's 2025 financial surplus of GHS 70 million indicates its operational capacity for such enforcement.
The FDA issued a public notice on Wednesday, September 2, detailing its findings. Laboratory analysis confirmed the presence of Sildenafil Citrate in Arcan Bitters, which was labelled as containing 35% alcohol by volume. The Authority stressed that registered alcoholic beverages must not contain any drug substances. This clear statement reinforces the regulatory framework governing product composition and labelling.
Consumers should immediately stop using Arcan Bitters and return any purchased bottles to the point of sale. The recall will likely lead to increased scrutiny of other herbal and alcoholic beverages on the market. Manufacturers must ensure strict adherence to FDA regulations to avoid similar penalties. This event serves as a strong reminder to all producers about the importance of product integrity and consumer safety. The FDA's swift response aims to prevent potential health risks associated with undeclared drug ingredients.
The economic implications for Unni Associates Company Limited are significant, including lost revenue and potential legal action. This incident could also impact consumer confidence in locally produced beverages. The FDA's decisive action protects consumers from potentially harmful substances. It also sends a clear message to manufacturers about the consequences of non-compliance. The Authority's vigilance is vital for maintaining a safe and reliable food and drug supply chain in Ghana. This case highlights the continuous need for robust regulatory oversight in the country's rapidly evolving consumer goods sector. The FDA remains committed to its mandate of protecting public health and safety.